Perform orthogonal validation using:
Western blotting: Compare wild-type vs. T-DNA insertion mutants (e.g., SALK_012345) to confirm absence of signal in mutants
Immunofluorescence: Validate subcellular localization against GFP-tagged At2g01130 lines
Peptide competition assays: Pre-incubate antibody with immunogen peptide (e.g., residues 50-75 of At2g01130) to confirm signal loss
Combine tyramide signal amplification with standard immunofluorescence
Use chemiluminescent substrates with extended exposure times (30min-2hr) in western blotting
Implement tandem affinity purification for co-IP experiments
Apply mixed-effects modeling for batch variations:
Implement quantile normalization across technical replicates
Use mathematical modeling of antibody turnover:
Sample at critical transitions:
Parallel antibody arrays: 40-plex Luminex assays for pathway analysis
Spatial transcriptomics correlation: MERFISH + antibody staining co-localization
CRISPR-Cas9 perturbation screens: Link antibody signals to genetic interactome
| Ecotype | SNP Frequency | Validation Approach |
|---|---|---|
| Col-0 | Reference | Baseline validation |
| Cvi-0 | 2.3 SNPs/kb | Epitope region sequencing |
| Sha | 1.8 SNPs/kb | Recombinant protein expression |
Apply translational scoring matrix:
| Criterion | Weight | Assessment Method |
|---|---|---|
| Structural conservation | 0.3 | Phyre2 homology modeling |
| Pathway essentiality | 0.4 | Essential gene databases |
| Disease association | 0.3 | OMIM/ClinVar cross-referencing |
Establish laboratory-specific validation criteria: